Alto Neuroscience, Inc.

ANRO

Explore Our Financial Data > Companies > California Companies > Alto Neuroscience, Inc.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	ANRO
CIK	0001999480
SIC	2834
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Pharmaceutical Preparations

Contact

Address	650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW, CA, 94041
Website	www.altoneuroscience.com
Phone	773-255-5012
CEO	Amit Etkin
Employees	N/A

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	N/A
Pre-Tax Income	$-63.18 million
Net Income	$-63.18 million
Net Income to Common	$-63.18 million
EPS	$-2.30

View All

Balance Sheet

Cash	$160.75 million
Assets	$171.92 million
Liabilities	$32.82 million
Common Equity	$139.10 million
Liabilities & Equity	$171.92 million

View All

Cash Flow Statement

Net Income	$-63.18 million
Cash From Operating Activities	$-53.00 million
Cash From Investing Activities	$-1.88 million
Cash From Financing Activities	$10.26 million
Change in Cash	$-44.62 million

View All

Calculations

NOPAT	$-48.93 million
EBITDA	$-69.42 million
Price to Earnings	N/A
Price to Book	$0.43
ROE	-38.04%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

MOUNTAIN VIEW, Calif., June 26, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the identification of a patient selection biomarker and positive pharmacodynamic results from its exploratory Phase 2 proof-of-concept (POC) trial of ALTO-203 in major depressive disorder (MDD) patients with elevated levels of anhedonia. ALTO-203 is a novel, oral, hist

Article Link

Regeneron makes obesity push; Atai, Alto ink brain drug deals

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Article Link

Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal

On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for treatment-resistant depression (TRD), generally defined as a failure on two or more antidepressants. Alto paid Chase Therapeutics an upfront payment of $1.75 million. Chase Therapeutics will be eligible for up to $71.5 million in milestone payments, $41 million of the potential future milestone payments are tied to t

Article Link

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

MOUNTAIN VIEW, Calif., June 03, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that it entered into an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of potentially best-in-class dopamine agonist drug combinations, including ALTO-207, formerly known as CTC-501, for treatment resistant depression (TRD), generally def

Article Link

Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

MOUNTAIN VIEW, Calif., May 29, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced a presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, in Scottsdale, Arizona, held May 27-30, 2025.

Article Link